Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Hanspeter NaegeliJean‐louis BressonTamas DalmayIan Crawford DewhurstMichelle M EpsteinLeslie George FirbankPhilippe GuercheJan HejatkoFrancisco Javier MorenoEwen MullinsFabien NoguéNils RostoksJose Juan Sánchez SerranoGiovanni SavoiniEve VeromannFabio VeronesiMichele ArdizzoneYann DevosSilvia FedericiAntonio Fernandez DumontAndrea GennaroJose Ángel Gómez RuizFranco Maria NeriNikoletta PapadopoulouKonstantinos ParaskevopoulosAnna Lanzoni
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans EFSA Journal le 01/11/2020

---

Résumé : Oilseed rape 73496 was developed to confer tolerance to the herbicidal active substance glyphosate through the expression of the glyphosate acetyltransferase protein GAT4621. The molecular characterisation data and bioinformatic analyses identify no issues requiring food/feed safety assessment. None of the identified differences between oilseed rape 73496 and its conventional counterpart in the agronomic/phenotypic endpoints tested needs further assessment. Differences identified in seed composition of oilseed rape 73496 as compared to its conventional counterpart raise no safety and nutritional concerns in the context of the scope of this application. No safety concerns are identified regarding toxicity and allergenicity of the GAT4621 protein as expressed in oilseed rape 73496. No evidence is found that the genetic modification would change the overall allergenicity of oilseed rape 73496. Based on the outcome of the comparative and nutritional assessments, the consumption of oilseed rape 73496 does not represent any nutritional concern, in the context of the scope of this application. The implementation of a post-market monitoring plan is recommended to confirm the predicted consumption data and to verify that the conditions of use are those considered during the pre-market risk assessment. In the case of accidental release of viable oilseed rape 73496 seeds into the environment, oilseed rape 73496 would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of oilseed rape 73496. The GMO Panel concludes that oilseed rape 73496, as described in this application, is as safe as its conventional counterpart and the non-genetically modified oilseed rape reference varieties tested with respect to potential effects on human and animal health and the environment.

---

Fichiers liés : EFSA Journal - 2021 - - Assessment of genetically modified oilseed rape 73496 for food and feed uses under Regulation EC.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Anne BlanchardKintur SanghviManish SaxenaPhilippe GosseJohn ReillyTerry LevyLars RumpAlexandre PersuJan BasileMichael BlochJoost DaemenMelvin D LoboFelix MahfoudRoland E SchmiederAndrew SharpBarthelemy von HallerMarc SapovalPete FongAtul PathakPierre LantelmeDavid HsiSripal BangaloreAdam WitkowskiJoachim WeilBenjamin KablyNeil BarmanHelen Reeve-StofferLeslie ColemanCandace McclureAjay J KirtaneJosh CostelloCourtney KrathanLuot LewisAndrew McelvarrStephen JenkinsMichael CashShannon WilliamsMaria JarvisCheryl LafferJames GainerMark RobbinsSherron CrookSarita MaddelScott MartinEdward PortnayMaryanne DuceySuzanne RoseElizabeth DelmastroStephen WilliamsStanley CabosCarolina Rodriguez AlvarezThomas TodoranEric PowersEmily HodskinsVijay PaladuguAnna TecklenburgChandan DevireddyJanice LeaBryan WellsAmanda FiebachClaudia MerlinFlorian RaderSuhail DohadHyun-Min KimMohammad RashidJosephine AbrahamTheophilus OwanAnu AbrahamIran LavasaniHailey NeilsonDavid CalhounThomas McelderryWilliam MaddoxSuzanne OparilSheila KinderJai RadhakrishnanCandido BatresSuzanne EdwardsJoseph GarasicDoug DrachmanRandy ZusmanKenneth RosenfieldDanny DoMatheen KhuddusSuzanne ZentkoJames O'MearaIlie BarbAbby FosterAlice BoyetteYale WangDesmond JayNedaa SkeikRobert SchwartzRose PetersonJo Anne GoldmanJessie GoldmanGary LedleyNancy KatofSrinivasa PotluriScott BiedermannJacquelyn WardMegan WhiteNaomi Dl FisherLaura MauriPiotr SobieszczkyAlex SmithLaura AseltineRick StoufferAlan HinderliterEric PauleyTyrone WadeDavid ZidarMehdi ShishehborBarry EffronMarco CostaTerence SemenecChanwit RoongsritongPriscilla NelsonBridget NeumannDebbie CohenJay GiriRobin NeubauerThu VoAtul ChughPei-Hsiu HuangPowell JoseJohn FlackRobert FishmanMichael JonesTodd AdamsChristopher BajzerAnthony MathurAjay JainArmida BalawonOlivier ZongoClare BentDavid BeckettNicki LakemanSarah KennardRichard d'SouzaSarah StattonLindsay WilkesChristine AnningJeremy SayerSudha Ganesh IyerNicholas RobinsonAnnaliza SevillanoMadelaine OcampoRobert GerberMohamad FarisAndrew John MarshallJanet SinclairHayley PepperJustin DaviesNeil ChapmanPaula BurakPaula CarvelliSachin JadhavJane QuinnLars Christian RumpJohannes StegbauerLars SchimmöllerSebastian PotthoffClaudia SchmidSylvia RoederLukas HaferTolga AgdirliogluTanja KöllnerMichael BöhmSebastian EwenSaarraaken KulenthiranAngelika WachterChristina KochPhilipp LurzKarl FenglerKarl-Philipp RommelKai TrautmannMartin PetzoldChristian OttAxel SchmidMichael UderUlrike HeinritzKerstin Fröhlich-EndresSabine Genth-ZotzDenise KämpfnerArmin GraweJohannes HöhneBärbel KaesbergerConstantin von Zur MühlenDennis WolfMarkus WelzelGudrun HeinrichsBarbara TrabitzschAntoine CremerHervé TrillaudPanteleimon PapadopoulosFlorent MaireJulie GaudissardErika CornuDavid FouassierMarine LivrozetAurélien LorthioirValérie PaquetBenjamin HontonMarianne CottinFrédéric PetitConstance BergePierre-Yves CourandFatou LangevinPascal DelsartBenjamin LongereGuillaume LedieuFrançois PontanaCoralie SommevilleFabien BertrandLida FeyzVictor ZeijenArno RuiterElisabeth HuyskenPeter BlankestijnMichiel VoskuilZwaantina RittersmaHelma DolmansA KroonW van ZwamJeannique VrankenClaudia de HaanJean RenkinFrédéric MaesChristophe BeauloyeJean-Philippe LengeléDominique HuyberechtsAnne BouvieAndrzej JanuszewiczJacek KdzielaAleksander PrejbisjDagmara HeringDariusz CiecwierzMilosz JaguszewskiRadoslaw Owczuk
• Organismes : Imagerie Ultrasonore Imagerie Ultrasonore
• Publié dans The Lancet le 02/11/2020

---

Fichiers liés : S0140673621007881.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Nathalie JustHans AdriaensenArsène EllaPierre-Marie ChevillardMartine BataillerJean-Philippe DuboisMatthieu KellerMartine Migaud
• Organismes : Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly]
• Publié dans Brain Research le 29/10/2020

---

Résumé : The ovine model could be an effective translational model but remains underexplored. Here, Blood Oxygen Level dependent functional MRI during visual stimulation and resting-state perfusion MRI were explored. We aimed at investigating the impact of isoflurane anesthesia during visual stimulation and evaluate resting cerebral blood flow and cerebral blood volume parameters in the lamb and adult sheep brain. BOLD fMRI and perfusion MRI after a bolus of DOTAREM were conducted in 4 lambs and 6 adult ewes at 3 T. A visual stimulation paradigm was delivered during fMRI at increasing isoflurane doses (1-3%). Robust but weak BOLD responses (0.21 +/- 0.08%) were found in the lateral geniculate nucleus (LGN) up to 3% isoflurane anaesthesia. No significant differences were found beween BOLD responses in the range 1 to 3% ISO (p > 0.05). However, LGN cluster size decreased and functional localization became less reliable at high ISO doses (2.5-3% ISO). BOLD responses were weaker in adult sheep than in lambs (4.6 +/- 1.5 versus 13.6 +/- 8.5; p = 0.08). Relative cerebral blood volumes (rCBV) and relative cerebral blood flows (rCBF) were significantly higher (p < 0.0001) in lambs than in adult sheep for both gray and white matter. The impact of volatile anesthesia was explored for the first time on BOLD responses demonstrating increased reliability of functional localization of brain activity at low doses. Perfusion MRI was conducted for the first time in both lambs and adult ewes. Assessment of baseline cerebrovascular values are of interest for future studies of brain diseases allowing an improved interpretation of BOLD responses.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Xiuzhi ChenPhilippe CiaisFabienne MaignanKaili ZhangAna BastosQingling SunCédric BacourSassan S SaatchiPierre GentineDaniel S GollJulia GreenHyungjun KimLaurent LiYi LiuBenjamin PoultHao TangNicolas ViovyWigneron J.-P.Jin WuWenping YuanHaicheng Zhang
• Organismes : National Sun Yat-sen University Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] ICOS-ATC Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation des Surfaces et Interfaces Continentales Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Laboratoire de Météorologie Dynamique (UMR 8539) Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Laboratoire de Météorologie Dynamique (UMR 8539) Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] NOVELTIS [Sté] Interactions Sol Plante Atmosphère Department of Earth and Environmental Engineering [New York] Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Contrôles des cycles biogéochimiques terrestres Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Institute of Industrial Science [Tokyo] Laboratoire de Météorologie Dynamique (UMR 8539) Nanjing University of Information Science and Technology Sino-French Institute for Earth System Science, College of Urban and Environmental Sciences Department of Geographical Sciences [College Park] National Sun Yat-sen University Interactions Sol Plante Atmosphère The University of Hong Kong Southern Marine Science and Engineering Guangdong Laboratory National Sun Yat-sen University Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette]
• Publié dans Global Biogeochemical Cycles le 25/10/2020

---

Résumé : Amazonian evergreen forests show distinct canopy phenology and photosynthetic seasonality but the climatic triggers are not well understood. This imposes a challenge for modeling leaf phenology and photosynthesis seasonality in land surface models (LSMs) across Amazonian evergreen forest biome. On continental scale, we tested two climatic triggers suggested by site observations, vapor pressure deficit (VPD), and short-wave incoming radiation (SW) for defining leaf shedding and incorporated VPD- and SW-triggered new canopy phenology modules in the ORCHIDEE LSM (hereafter VPD-AP and SW-AP versions). Our results show that both VPD and SW are plausible precursors of large scale litterfall seasonality across the basin by comparing against in situ data from 14 sites. Specially, both VPD-AP and SW-AP correctly capture the increases in litterfall during the early dry season, followed by a flush of new leaves with increasing photosynthetic rates during the later dry season. The VPD-AP version performs better than the SW-AP version in capturing a dry-season increase of photosynthesis across the wet Amazonia areas where mean annual precipitation exceeds 2,000 mm yr$^{-1}$, consistent with previous satellite data analysis. Both VPD-AP and SW-AP model versions perform well in northern, central and southern Amazon regions where the SW seasonality is unimodal, but miss the seasonality of satellite GPP proxies in the eastern region off the coast of Guyana shield where SW seasonality is bimodal. Our findings imply that atmospheric dryness and sunlight availability likely explain the seasonality of leaf shedding and leaf flush processes, respectively, and consequently control canopy photosynthesis in Amazonian evergreen forests

---

Fichiers liés : 2020GB006893.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Xavier MoissetAudrey-Anne FouchardBruno PereiraFrederic TaitheGuillaume MatheyGilles EdanJonathan CironBruno BrochetJérôme de SèzeCaroline PapeixPatrick VermerschPierre M LabaugeGilles DeferChristine Lebrun-FrénayThibault MoreauDavid-Axel LaplaudEric BergerJean PelletierBruno StankoffOlivier GoutEric ThouvenotOlivier HeinzlefAbdullatif Al-KhedrBertrand BourreOlivier CasezPhilippe CabreAlexis MontcuquetAlain CreangeJean-Philippe CamdessanchéSerge BakchineAude MauroussetKarolina HankiewiczCorinne PottierNicolas MaubeugeDalia Dimitri BoulosChantal NifleSandra VukusicPierre Clavelou
• Organismes : CHU Clermont-Ferrand CHU Clermont-Ferrand CHU Clermont-Ferrand CHU Clermont-Ferrand Adaptation, mesure et évaluation en santé. Approches interdisciplinaires Service de neurologie [CHRU Nancy] Centre d'Investigation Clinique [Rennes] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire de Toulouse Université de Bordeaux Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier Universitaire [Strasbourg] CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Régional Universitaire [CHU Lille] Hôpital Lapeyronie [CHU Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Hôpital Pasteur [Nice] Centre d'épidémiologie des populations Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de Recherche en Transplantation et Immunologie Centre Hospitalier Régional Universitaire de Besançon Hôpital de la Timone [CHU - APHM] CHU Saint-Antoine [AP-HP] Fondation Ophtalmologique Adolphe de Rotschild Institut de Génomique Fonctionnelle CHI Poissy-Saint-Germain CHU Amiens-Picardie CHU Rouen Centre Hospitalier Universitaire [CHU Grenoble] Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] CHU Limoges CHU Henri Mondor [Créteil] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Hôpital universitaire Robert Debré [Reims] CHU Trousseau [Tours] Centre Hospitalier de Saint-Denis [Ile-de-France] Centre Hospitalier René Dubos [Pontoise] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre Hospitalier Versailles, 78000 Le Chesnay, France Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Université Claude Bernard Lyon 1 CHU Clermont-Ferrand
• Publié dans European Journal of Neurology le 22/10/2020

---

Résumé : Background and purpose: Disease-modifying therapies (DMTs) have an impact on relapses and disease progression. Nonetheless, many patients with multiple sclerosis (MS) remain untreated. The objectives of the present study were to determine the proportion of untreated patients with MS followed in expert centers in France and to determine the predictive factors of nontreatment. Methods: We conducted a retrospective cohort study. Data were extracted from the 38 centers participating in the European Database for Multiple Sclerosis (EDMUS) on December 15, 2018, and patients with MS seen at least once during the study period (from June 15, 2016 to June 14, 2017) were included. Results: Of the 21,189 patients with MS (age 47.1 +/- 13.1 years; Expanded Disability Status Scale (EDSS) score 3.4 +/- 2.4), 6,631 (31.3%; 95% confidence interval [CI] 30.7-31.9) were not receiving any DMT. Although patients with a relapsing-remitting course (n = 11,693) were the most likely to receive DMT, 14.8% (95% CI 14.2-15.4) were still untreated (6.8% never treated). After multivariate analysis among patients with relapsing-remitting MS, the main factors explaining never having been treated were: not having >= 9 lesions on brain magnetic resonance imaging (odds ratio [OR] 0.52 [95% CI 0.44-0.61]) and lower EDSS score (OR 0.78 [95% CI 0.74-0.82]). Most patients with progressive MS (50.4% for secondary and 64.2% for primary progressive MS) did not receive any DMT during the study period, while 11.6% of patients with secondary and 34.0% of patients with primary progressive MS had never received any DMT. Conclusion: A significant proportion of patients with MS did not receive any DMT, even though such treatments are reimbursed by the healthcare system for French patients. This result highlights the unmet need for current DMTs for a large subgroup of patients with MS.

---

Fichiers liés : Moisset et al - 2021 - Untreated patients with multiple sclerosis.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Joel BergéLaura BaudisPhilippe BraxSheng-Wey ChiowBruno ChristopheOlivier DoréPierre FayetAurélien HeesPhilippe JetzerClaus LämmerzahlMeike ListGilles MetrisMartin Pernot-BorràsJustin ReadSerge ReynaudChristian L. ReichardtBenny RieversManuel Jorge RodriguesTimothy SumnerJean-Philippe UzanNan Yu
• Organismes : DPHY, ONERA, Université Paris Saclay [Châtillon] Physik-Institut [Zürich] Institut de Physique Théorique - UMR CNRS 3681 Jet Propulsion Laboratory DPHY, ONERA, Université Paris Saclay [Châtillon] Jet Propulsion Laboratory Champs, Gravitation et Cordes Systèmes de Référence Temps Espace Physik-Institut [Zürich] Center of Applied Space Technology and Microgravity German Aerospace Center Géoazur DPHY, ONERA, Université Paris Saclay [Châtillon] Department of Physics, University of Surrey Laboratoire Kastler Brossel Jet Propulsion Laboratory Center of Applied Space Technology and Microgravity DPHY, ONERA, Université Paris Saclay [Châtillon] Blackett Laboratory Institut d'Astrophysique de Paris Jet Propulsion Laboratory
• Publié dans Experimental Astronomy le 29/10/2020

---

Résumé : We speculate on the development and availability of new innovative propulsion techniques in the 2040s, that will allow us to fly a spacecraft outside the Solar System (at 150 AU and more) in a reasonable amount of time, in order to directly probe our (gravitational) Solar System neighborhood and answer pressing questions regarding the dark sector (dark energy and dark matter). We identify two closely related main science goals, as well as secondary objectives that could be fulfilled by a mission dedicated to probing the local dark sector: (i) begin the exploration of gravitation’s low-acceleration regime with a spacecraft and (ii) improve our knowledge of the local dark matter and baryon densities. Those questions can be answered by directly measuring the gravitational potential with an atomic clock on-board a spacecraft on an outbound Solar System orbit, and by comparing the spacecraft’s trajectory with that predicted by General Relativity through the combination of ranging data and the in-situ measurement (and correction) of non-gravitational accelerations with an on-board accelerometer. Despite a wealth of new experiments getting online in the near future, that will bring new knowledge about the dark sector, it is very unlikely that those science questions will be closed in the next two decades. More importantly, it is likely that it will be even more urgent than currently to answer them. Tracking a spacecraft carrying a clock and an accelerometer as it leaves the Solar System may well be the easiest and fastest way to directly probe our dark environment.

---

Fichiers liés : Bergé2021_Article_TheLocalDarkSector.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Ronald Enrique Morales VargasT. TsunodaJ. NodaPhilippe BoussèsT.Y. NguyenF. HasebeJean-Pierre Dujardin
• Organismes : Mahidol University [Bangkok] Nagasaki University Rakuno Gakuen University [Japan] Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle National Institute of Hygiene and Epidemiology / Institut National d'Hygiène et d'Épidémiologie [Hanoi, Vietnam] Nagasaki University Interactions hôtes-vecteurs-parasites-environnement dans les maladies tropicales négligées dues aux trypanosomatides
• Publié dans Infection, Genetics and Evolution le 27/10/2020

---

Résumé : Japanese encephalitis is a severe disease of acute encephalitis, with children and the elderly primarily affected, and with mortality rates reaching over 25%. The virus is transmitted mainly by species of the Culex (Culex) vishnui subgroup, primarily the widely spread Cx. tritaeniorhynchus Giles. The latter is known as a highly migratory mosquito which moves with airflow over large distances. We explored the geometric variation of the wing venation among distant areas of its geographic distribution. Our working hypothesis was that shape variation across geography could reveal known past and present migratory routes.

---

Fichiers liés : S1567134821000617.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : David TougeronBarbara Seitz Seitz-PolskiMaxime HentzienFirouzé Bani-SadrJean BourhisMichel DucreuxSébastien GaujouxPhilippe GorpheBoris GuiuAnne Claire Hardy-BessardKhê Hoang XuanFlorence HuguetThierry LecomteAstrid LièvreChristophe LouvetLéon MaggioriPascale MarianiPierre MichelAmélie ServettazJuliette ThariatVirginie WesteelThomas AparicioJean-Yves BlayOlivier Bouché
• Organismes : Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU Nice [Cimiez] Hôpital universitaire Robert Debré [Reims] Hôpital universitaire Robert Debré [Reims] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] UNICANCER Institut Gustave Roussy Département de médecine oncologique [Gustave Roussy] CHU Pitié-Salpêtrière [AP-HP] Institut Gustave Roussy Département de cancérologie cervico-faciale [Gustave Roussy] Centre Hospitalier Régional Universitaire [Montpellier] Institut Desbrest d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Institut Universitaire de Cancérologie [Sorbonne Université] CHU Trousseau [Tours] Chemistry, Oncogenesis, Stress and Signaling Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Cooperator Multidisciplinary Oncology Group Hopital Saint-Louis [AP-HP] Institut Curie [Paris] Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Hôpital universitaire Robert Debré [Reims] Centre Régional de Lutte contre le Cancer François Baclesse [Caen] Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) Hopital Saint-Louis [AP-HP] Centre Léon Bérard [Lyon] Hôpital universitaire Robert Debré [Reims]
• Publié dans Bulletin du Cancer le 01/11/2020

---

Résumé : The COVID-19 pandemic has a major impact at all stages of cancer treatment. Risk of death from COVID-19 in patients treated for a cancer is high. COVID-19 vaccines represent a major issue to decrease the rate of severe forms of the COVID-19 cases and to maintain a normal cancer care. It is difficult to define the target population for vaccination due to the limited data available and the lack of vaccine doses available. It appears theoretically important to vaccinate patients with active cancer treatment or treated since less than three years, as well as their family circle. In France, patients actually defined at "high risk" for priority access to vaccination are those with a cancer treated by chemotherapy. A panel of experts recently defined another "very high-priority" population, which includes patients with curative or palliative first or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large lung volume, lymph nodes and/or of hematopoietic tissue. Ideally, it is best to vaccinate before cancer treatment. Despite the lack of published data, COVID-19 vaccines can also be performed during chemotherapy by avoiding periods of bone marrow aplasia and if possible, to do it in cancer care centers. It is necessary to implement cohorts with immunological and clinical monitoring of vaccinated cancer patients. To conclude, considering the current state of knowledge, the benefit-risk ratio strongly favours COVID-19 vaccination of all cancer patients.

---

Fichiers liés : Tougeron et al-2021-Vaccination contre la COVID-19 des patients atteints de cancer solide.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : Annie LaquerriereDana JaberEmanuela AbiusiJérome MaluendaDan MejlachowiczAlexandre VivantiKlaus DieterichRadka StoevaLoic QuevarecFlora NolentValérie BiancalanaPhilippe LatourDamien SternbergYline CapriAlain VerloesBettina BessieresLaurence LoeuilletTania Attie-BitachJelena MartinovicSophie BlessonFlorence PetitClaire BeneteauSandra WhalenFlorent MarguetJerome BouligandDelphine HéronGéraldine ViotJeanne AmielDaniel AmramCéline BellesmeMartine BucourtLaurence FaivrePierre-Simon JoukSuonavy KhungSabine SigaudyAnne-Lise DelezoideAlice GoldenbergMarie-Line JacquemontLaetitia LambertValérie LayetStanislas LyonnetArnold MunnichLionel van MaldergemJuliette PiardFabien GuimiotPierre LandrieuPascaline LetardFanny PelluardLaurence PerrinMarie-Hélène Saint-FrisonHaluk TopalogluLaetitia TrestardCatherine Vincent-DelormeHelge AmthorChristine BarneriasAlexandra BenachiEric BiethElise BoucherValerie Cormier-DaireAndrée Delahaye-DuriezIsabelle DesguerreBruno EymardChristine FrancannetSarah GrottoDidier LacombeFanny LaffargueMarine LegendreDominique Martin-CoignardAndré MegarbanéSandra MercierMathilde NizonLuc RigonnotFabienne PrieurChloé QuelinHanitra Ranjatoelina-RandrianaivoNicoletta RestaA ToutainHelene VerhelstMarie VincentEstelle ColinCatherine Fallet-BiancoMichèle GranierRomulus GrigorescuJulien SaadaMarie GonzalesAnne Guiochon-MantelJean-Louis BessereauMarcel TawkIvo GutCyril GitiauxJudith Melki
• Organismes : UNIROUEN - UFR Santé Université Paris-Saclay Université Paris-Saclay Université Paris-Saclay Laboratoire de Cancérologie Expérimentale Université Paris-Saclay [GIN] Grenoble Institut des Neurosciences Centre de Recherches en Cancérologie de Toulouse Centre Hospitalier Le Mans (CH Le Mans) Laboratoire d'écotoxicologie des radionucléides Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] Institut de Génétique et de Biologie Moléculaire et Cellulaire Hospices Civils de Lyon Centre de recherche en Myologie – U974 SU-INSERM Institut de Myologie Hôpital Robert Debré Hôpital Robert Debré Hôpital Necker - Enfants Malades [AP-HP] UFR Médecine [Santé] - Université Paris Cité Hôpital Necker - Enfants Malades [AP-HP] Université Paris Descartes - Paris 5 Imagine - Institut des maladies génétiques (IHU) AP-HP - Hôpital Antoine Béclère [Clamart] Centre Hospitalier Régional Universitaire de Tours Maladies RAres du DEveloppement embryonnaire et du MEtabolisme : du Phénotype au Génotype et à la Fonction - ULR 7364 Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Trousseau [APHP] Département de Pathologie [CHU Rouen] Team 4 NeoVasc - Region Team ERI 28 INSERM Physiologie et physiopathologie endocriniennes CHU Pitié-Salpêtrière [AP-HP] Clinique de la Muette Imagine - Institut des maladies génétiques (IHU) CHI Créteil Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Jean Verdier [AP-HP] Lipides - Nutrition - Cancer [Dijon - U1231] Biologie Computationnelle et Modélisation Maladies neurodéveloppementales et neurovasculaires CHU Marseille Hôpital de la Timone [CHU - APHM] Maladies neurodéveloppementales et neurovasculaires Service de Génétique [CHU Rouen] Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Centre Hospitalier Universitaire de La Réunion V MANE Fils Groupe Hospitalier du Havre Imagine - Institut des maladies génétiques (IHU) Imagine - Institut des maladies génétiques (IHU) Centre de génétique humaine [CHRU Besançon] Centre de génétique humaine [CHRU Besançon] Maladies neurodéveloppementales et neurovasculaires Molecular and pathophysiological bases of cognitive disorders Imagine - Institut des maladies génétiques Maladies neurodéveloppementales et neurovasculaires Bordeaux Research In Translational Oncology [Bordeaux] Centre Hospitalier Universitaire de Bordeaux Département de génétique [Robert Debré] Maladies neurodéveloppementales et neurovasculaires Hacettepe University Children's Hospital Clinique du Belvédère Centre Hospitalier Régional Universitaire [CHU Lille] Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologies appliquées Hôpital Necker - Enfants Malades [AP-HP] AP-HP - Hôpital Antoine Béclère [Clamart] Université Paris-Saclay Centre Hospitalier Universitaire de Toulouse Imagine - Institut des maladies génétiques (IHU) Maladies neurodéveloppementales et neurovasculaires Hôpital Necker - Enfants Malades [AP-HP] Institut de Myologie CHU Pitié-Salpêtrière [AP-HP] CHU Estaing [Clermont-Ferrand] AP-HP Hôpital universitaire Robert-Debré [Paris] CHU de Bordeaux Pellegrin [Bordeaux] Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) Assistance publique - Hôpitaux de Paris (AP-HP) CHU Clermont-Ferrand Hôpital Pellegrin, CHU de Bordeaux Centre Hospitalier Le Mans (CH Le Mans) Lebanese American University Institut Jérôme Lejeune Centre Hospitalier Universitaire de Nantes = Nantes University Hospital ITX - unité de recherche de l'institut du thorax Service de génétique médicale - Unité de génétique clinique [Nantes] Centre Hospitalier Sud Francilien Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre de référence Maladies Rares CLAD-Ouest [Rennes] Hôpital Sud [CHU Rennes] Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro Imaging, Brain & Neuropsychiatry Service de génétique [Tours] Ghent University Hospital Département de pédiatrie [CHU Nantes] Centre Hospitalier Universitaire d'Angers Département de pathologie et biologie cellulaire Médecine néonatale CHU Trousseau [APHP] AP-HP - Hôpital Antoine Béclère [Clamart] CHU Trousseau [APHP] Service de Génétique Moléculaire Pharmacogénétique et Hormonologie [CHU Bicêtre] Institut NeuroMyoGène Maladies et hormones du système nerveux Centre for Genomic Regulation - Centre de Regulació Genòmica [Barcelona] Hôpital Necker - Enfants Malades [AP-HP] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
• Publié dans Journal of Medical Genetics le 26/10/2020

---

Résumé : BACKGROUND: Arthrogryposis multiplex congenita (AMC) is characterised by congenital joint contractures in two or more body areas. AMC exhibits wide phenotypic and genetic heterogeneity. Our goals were to improve the genetic diagnosis rates of AMC, to evaluate the added value of whole exome sequencing (WES) compared with targeted exome sequencing (TES) and to identify new genes in 315 unrelated undiagnosed AMC families. METHODS: Several genomic approaches were used including genetic mapping of disease loci in multiplex or consanguineous families, TES then WES. Sanger sequencing was performed to identify or validate variants. RESULTS: We achieved disease gene identification in 52.7% of AMC index patients including nine recently identified genes (CNTNAP1, MAGEL2, ADGRG6, ADCY6, GLDN, LGI4, LMOD3, UNC50 and SCN1A). Moreover, we identified pathogenic variants in ASXL3 and STAC3 expanding the phenotypes associated with these genes. The most frequent cause of AMC was a primary involvement of skeletal muscle (40%) followed by brain (22%). The most frequent mode of inheritance is autosomal recessive (66.3% of patients). In sporadic patients born to non-consanguineous parents (n=60), de novo dominant autosomal or X linked variants were observed in 30 of them (50%). CONCLUSION: New genes recently identified in AMC represent 21% of causing genes in our cohort. A high proportion of de novo variants were observed indicating that this mechanism plays a prominent part in this developmental disease. Our data showed the added value of WES when compared with TES due to the larger clinical spectrum of some disease genes than initially described and the identification of novel genes.

---

Fichiers liés : PDF Datastream.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/06/2021
• Auteurs : A. LaurentAlicia FournierAnne-Laure PoujolVictoire DeltourFlorent LheureuxNicolas Meunier-BeillardMélanie LoiseauFiona EcarnotJean-Philippe RigaudC BinquetJean-Pierre Quenot
• Organismes : Laboratoire de psychologie : dynamiques relationnelles et processus identitaires [Dijon] Laboratoire de psychologie : dynamiques relationnelles et processus identitaires [Dijon] École de Psychologues Praticiens Laboratoire de psychologie : dynamiques relationnelles et processus identitaires [Dijon] Laboratoire de Psychologie - UFC (UR 3188) Institut National de la Santé et de la Recherche Médicale Centre Ressources Autisme de Bourgogne (CHU de Dijon) Service de médecine légale (Institut médico-légal et Unité médico-judiciaire) (CHU de Dijon) Cellule d'urgence médico-psychologique Centre Hospitalier Régional Universitaire de Besançon Service de Médecine Intensive Réanimation (CH Dieppe) Espace de réflexion éthique de Normandie Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Service de Réanimation Médicale (CHU de Dijon)
• Publié dans Médecine Intensive Réanimation le 23/10/2020

---

Résumé : Alors que l’infection à SARS-COV-2 s’est rapidement propagée au niveau mondial, on a assisté à une mobilisation massive des soignants auprès des personnes infectées. En réanimation, les conditions de travail déjà habituellement difficiles se sont durcies, avec une augmentation forte de la charge de travail, une nécessaire et indispensable réorganisation des soins, des décisions complexes relatives à l’admission des patients et une modification de l’accueil des familles. Le tout dans un climat d’incertitude générale et d’insécurité personnelle. Cet article propose une mise au point sur l’impact psychologique de cette crise sur les soignants en réanimation et les possibles dispositifs d’accompagnement à partir des données récentes de la littérature et notamment des données issues de l’étude PsyCOVID-ICU coordonnée par les auteurs de cet article.

---

Source